Ignite Hope

Precision Oncology Summit 2022

19 May 2022



Event details

19 May, 2022

Singapore

09:30 a.m. (GMT+8)

Seoul, S.Korea Tokyo, Japan

10:30 a.m. (GMT +9)

Sydney, Australia 12:30 p.m. (GMT +11)

Agenda

Track 1: New Frontiers in Precision Oncology: EpiGenomics, Liquid Biopsy and Comprehensive Profiling

09:30 a.m. - 09:40 a.m. Welcome Address

Dr. Charmian Cher, Director of Regional Marketing, South Asia Pacific,

Japan and S.Korea

Agilent Technologies, Singapore

09:40 a.m. – 10:05 a.m. (Epi)Genomic Mechanisms of Gastric Cancer - Opportunities for

Translational Insights and Precision Oncology

Prof. Patrick Tan, Professor, Cancer and Stem Cell Biology Programme,

Duke-NUS Medical School, Singapore

10:05 a.m. - 10:25 a.m. Development and Validation of a Targeted Lymphoma Specific Gene Panel

for the Detection of Somatic Mutations from Cell-Free DNA

Dr. Stephen Wong, Senior Research Officer, Postdoctoral Fellow Cancer

Biology & Therapeutics Program

Peter MacCallum Cancer Centre, Australia

10:25 a.m. – 11:00 a.m. In house operation of screening genomic testing for cancer

Prof. Hiroshi Nishihara, Professor, Genomics Unit, Keio Cancer Centre

Keio University School of Medicine, Japan

11:00 a.m. – 11:15 a.m. Comprehensive Genomic Profiling with a Catalog: SureSelect Cancer Panel

Dr. Felicity J Hall, Senior Global Product Manager for NGS,

Diagnostics and Genomics Group Agilent Technologies, USA

11:15 a.m. – 11:30 a.m. Clinical Utility of Comprehensive NGS Liquid Biopsy Including Acquired

Resistance Monitoring
Mr Mark Li, President and CEO

Resolution Bioscience, USA

11:30 a.m. – 12:00 p.m. Live Q&A with Panelists

Hosted by Q&A Chairperson

Rebecca Brandes, Oncology Market Development, Companion Diagnostics

Agilent Technologies, USA

For research use only. Not for use in diagnostic procedures. PR7000-8568



Ignite Hope

Precision Oncology Summit 2022

19 May 2022



Event details

19 May, 2022

Singapore

09:30 a.m. (GMT+8)

Seoul, S.Korea Tokyo, Japan

10:30 a.m. (GMT +9)

Sydney, Australia 12:30 p.m. (GMT +11)

Agenda

Track 2: Clinically Significant Biomarkers and the Future of Tissue Pathology

09:30 a.m. - 09:40 a.m. Welcome Address

Dr. Charmian Cher, Director of Regional Marketing, South Asia Pacific,

Japan and S.Korea

Agilent Technologies, Singapore

09:40 a.m. - 10:10 a.m. Triple Negative Breast Cancer: Tying molecular point of view to innovative

prognostic and predictive roles, with decisive impact on clinical outcomes

Dr. Mastura Md. Yusof, Head of Oncology Services and Consultant

Clinical Oncologist

Pantai Hospital Kuala Lumpur, Malaysia

10:10 a.m. – 10:40 a.m. Triple-negative Breast Cancer (TNBC): A Pathologist's Perspective

Dr. Tay Kwang Yong, Timothy, Consultant Pathologist

Singapore General Hospital, Singapore

10:40 a.m. – 11:10 a.m. MMR/MSI Clinical Value and Test Methods in Immunotherapy

Prof. Sheng Weiqi, Professor and Director of Pathology, Doctorate Mentor

Fudan University Shanghai Cancer Centre, China

11:10 a.m. – 11:30 a.m. Slide-Based Tissue Multiplex Assays for Companion Diagnostics

Dr. Mark Verardo, Senior Scientific Program Manager, Companion Diagnostics

Agilent Technologies, USA

Dr. Jim Christian, Staff Pathologist, Companion Diagnostics

Agilent Technologies, USA

11:30 a.m. - 12:00 p.m. Live Q&A with Panelists

Hosted by Q&A Chairperson:

Dr. Lim Kok Hing, Consultant Pathologist, Department of Anatomical Pathology

Singapore General Hospital, Singapore

For research use only. Not for use in diagnostic procedures, D70679 01

